» Articles » PMID: 21182075

Differences in the Production of Spliced Antigenic Peptides by the Standard Proteasome and the Immunoproteasome

Overview
Journal Eur J Immunol
Date 2010 Dec 25
PMID 21182075
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Peptide splicing allows the production of antigenic peptides composed of two fragments initially non-contiguous in the parental protein. The proposed mechanism of splicing is a transpeptidation occurring within the proteasome. Three spliced peptides, derived from FGF-5, melanoma protein gp100 and nuclear protein SP110, have been described. Here, we compared the production of these spliced peptides by the standard proteasome and the immunoproteasome. Differential isotope labelling was used to quantify (by mass spectrometry) the fragments contained in digests obtained with precursor peptides and purified proteasomes. The results show that both the standard and the immunoproteasomes can produce spliced peptides although they differ in their efficiency of production of each peptide. The FGF-5 and gp100 peptides are more efficiently produced by the standard proteasome, whereas the SP110 peptide is more efficiently produced by the immunoproteasome. This seems to result from differences in the production of the two splicing partners, which depends on a balance between cleavages liberating or destroying those fragments. By showing that splicing depends on the efficiency of production of the splicing partners, these results also support the transpeptidation model of peptide splicing. Furthermore, given the presence of immunoproteasomes in dendritic cells and cells exposed to IFN-γ, the findings may be relevant for vaccine design.

Citing Articles

Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing.

Soh W, Roetschke H, Cormican J, Teo B, Chiam N, Raabe M Nat Commun. 2024; 15(1):1147.

PMID: 38326304 PMC: 10850103. DOI: 10.1038/s41467-024-45339-3.


Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example.

Lichti C, Wan X Semin Immunol. 2023; 66:101730.

PMID: 36827760 PMC: 10324092. DOI: 10.1016/j.smim.2023.101730.


InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides.

Roetschke H, Rodriguez-Hernandez G, Cormican J, Yang X, Lynham S, Mishto M Sci Data. 2023; 10(1):18.

PMID: 36627305 PMC: 9832164. DOI: 10.1038/s41597-022-01890-6.


An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool.

Verkerk T, Koomen S, Fuchs K, Griffioen M, Spaapen R Proc Natl Acad Sci U S A. 2022; 119(29):e2119736119.

PMID: 35858315 PMC: 9303865. DOI: 10.1073/pnas.2119736119.


Neo-Splicetopes in Tumor Therapy: A Lost Case?.

Kloetzel P Front Immunol. 2022; 13:849863.

PMID: 35265089 PMC: 8898901. DOI: 10.3389/fimmu.2022.849863.